The Fragile X Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Fragile X Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued products.
GlobalData tracks 50 drugs in development for Fragile X Syndrome by 41 companies/universities/institutes. The top development phase for Fragile X Syndrome is preclinical with 28 drugs in that stage. The Fragile X Syndrome pipeline has 49 drugs in development by companies and one by universities/ institutes. Some of the companies in the Fragile X Syndrome pipeline products market are: Nova Mentis BioTech, Epigen Biosciences and Healx.
The key targets in the Fragile X Syndrome pipeline products market include 5-Hydroxytryptamine Receptor 2A, Fragile X Messenger Ribonucleoprotein 1, and Sigma Non Opioid Intracellular Receptor 1.
The key mechanisms of action in the Fragile X Syndrome pipeline product include 5-Hydroxytryptamine Receptor 2A Agonist with four drugs in Preclinical. The Fragile X Syndrome pipeline products include four routes of administration with the top ROA being Oral and five key molecule types in the Fragile X Syndrome pipeline products market including Small Molecule, and Gene Therapy.
Fragile X Syndrome overview
Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1, and occurs both in males and females. Symptoms include delay in crawling, walking, or twisting; hyperactive or impulsive behavior; speech and language delay; and intellectual disability.
For a complete picture of Fragile X Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
